In Brief: Genzyme Seprafilm
This article was originally published in The Gray Sheet
Genzyme Seprafilm: Company submits premarket approval application for bioresorbable membrane designed to reduce postoperative adhesion formation in open abdominal and pelvic procedures. The PMA will undergo expedited review at FDA. Last week, Genzyme reported the results of a study showing that 51% of abdominal surgery patients treated with Seprafilm do not develop adhesions 8-12 weeks following surgery ("The Gray Sheet" Oct. 30, In Brief)...
You may also be interested in...
Unilever North America agrees SmartyPant, founded in 2011 to create a comprehensive supplement made from premium ingredients to support the wellbeing needs of children and adults. Kind, fully owned by Mars, has an agreement to acquire family-owned Nature's Bakery which offers snacks including fig bars and other soft-baked foods.
Arcadia prohibited from arguing against Advantice’s appeal of National Advertising Division decision that Kerasal Fungal Nail Renewal ad claims weren’t supported. Arcadia violated confidentiality rule by publicizing NAD decision before the review was officially closed.
The C-suite leaders schemed to falsely record shipments of unwanted products to distributors as sales so the company could meet revenue projections, the government charged.